Most current immunotherapies like anti-PD-1 and anti-CTLA4 monoclonal antibodies are designed to activate T cells by targeting immune checkpoint molecules. Despite the unprecedented durable response rates observed with immune checkpoint blockades, efficacy is limited in the majority of treated patients by a key barrier: the immunosuppressive tumor microenvironment. Particularly immune checkpoint blockades are largely ineffective in pancreatic, breast and colon cancers that exhibit relatively low T cell infiltration (termed as immunologically “cold”).
Immunosuppression in microenvironment of the cold tumors is orchestrated by the activity of a variety of stromal myeloid and lymphoid cells, such as tumor-associated macrophages and regulatory T cells, often through secretion of immunosuppressive cytokines. By utilizing translational medicine approaches, Elixiron’s scientists have identified key immunosuppressive cytokines from the microenvironment of cold tumors, which not only drive immune resistance but also promote cancer progression. We are committed to the development of revolutionary immunotherapies targeting the immunosuppressive tumor microenvironment to harness the full power of the immune system to fight cancer.